Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …

Limited treatment options are available for lung cancer with brain metastases. Recent
reports indicated that erlotinib and pemetrexed had synergistic effects in lung …

Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …

Purpose Recent reports indicate that refractory central nervous system (CNS) metastases of
non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib …

Purpose Several cases have been reported in which central nervous system (CNS)
metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by …

Background: Brain metastases commonly occur in non–small cell lung cancer (NSCLC), and
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor …

Gefitinib—a specific inhibitor of epidermal growth factor receptor (EGFR)-associated tyrosine
kinase—has demonstrated efficacy in a subgroup of patients with non-small-cell lung …

Purpose We have treated patients with non-small-cell lung cancer (NSCLC) who developed
leptomeningeal metastases (LM) during gefitinib therapy, and then found symptomatic …

Leptomeningeal metastases (LM) occur in 5–10% of patients with solid tumors and are
associated with a dismal prognosis. We describe LM from lung adenocarcinoma harboring a …

Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …